EYEkaterina E. Yakovleva

Ekaterina E. Yakovleva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ekaterina E. Yakovleva has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigation of imidazole-4,5-dicarboxylic acid derivatives activity on visceral pain in mice

    by Ekaterina E. Yakovleva, Mekchriniso T. Kamalova, Varvara G. Yakovleva, Maria A. Brusina, Evgeny R. Bychkov, Petr D. Shabanov

    Introduction: Glutamate plays an important role in the modulation of nociception. Experimental studies on rodents have shown that mGluR1 receptor inhibitors demonstrate antinociceptive potential in acute pain models. New ligands of the glutamate NMDA-receptor complex are imidazole-4,5-dicarboxylic acid derivatives, which conformational rigidity allows increasing selectivity interaction and decreasing a number of side effects with the implementiation a high analgesic potential. Materials and Methods: Intraperitoneal administration of algogen – 1.5% acetic acid solution –causes chemical pain irritation, manifested by specific animal movements called writhing. Fifteen minutes before the administration of 1.5% acetic acid solution, mice were intraperitoneally administered the experimental substances: IEM-303 at a dose of 50 mg/kg and IEM-2347 at doses of 10, 20, and 40 mg/kg. The control group of animals received a physiological solution in an equivalent volume, and the comparison group received metamizole sodium at a dose of 100 mg/kg. The analgesic effect was assessed by the ability of the drugs to reduce the number of writhings in comparison with the control group. Results: The introduction of substance IEM-2347 at a concentration of 10 mg/kg led to a decrease in the number of writhings to 6.3 ± 3.1 units (by 89.4%), which significantly exceeds the indicators obtained in the group receiving metamizole sodium. With a further increase in IEM-2347 concentration to 20-40 mg/kg, complete suppression of the pain response was observed in 100% of animals. Discussion: It can be assumed that the elongation of radicals in the benzene ring at nitrogen atoms has an effect enhancing the analgesic potential of the imidazole dicarboxylic acid derivative. Conclusion: High analgesic potential with toxicological safety of imidazole-4,5-dicarboxylic acid derivatives allows them to be considered as promising pain relievers.

  • Open Access

    Pharmacologic management of pain in intraoperative and postoperative periods in pediatric practice

    by Ekaterina E. Yakovleva, Eugenii R. Bychkov, Anna N. Galustyan, Natalia A. Kuritsina, Eugenii V. Mokrenko, Polina A. Makarova, Petr D. Shabanov

    Pain management, along with the prevention of infectious complications, is among the primary objectives of the perioperative period. In infants and newborns, intense pain triggers a stress response. In similar surgical interventions, the stress response activated by afferent neuronal impulses from the site of injury in newborns is greater in magnitude but shorter compared with that in adults. Effective analgesia with opioids during cardiac surgery has been shown to improve surgical outcomes. Prolonged, high-intensity pain in a newborn with ineffective analgesia leads to the progression of such pathological conditions as hypoxia, metabolic acidosis, impaired liver and kidney function, an increased risk of sepsis, disseminated intravascular coagulation, and higher neonatal mortality. At present, the capabilities of traditional analgesia methods remain limited. In this regard, the main approaches to improving the efficacy of pain management in pediatric practice include various regimens combining non-opioid analgesics, supplemented with opioids if necessary, as well as the development of new effective and safe pharmacologic agents with analgesic activity.

  • Open Access

    Practical recommendations for neonatologists and pediatricians “Congenital ureaplasma, mycoplasma and chlamidia infections” (Draft of clinical recommendations for discussion by specialists)

    by Dmitry O. Ivanov, Elena V. Bem, Alexandra S. Panchenko, Ekaterina N. Balashova, Galina N. Chumakova, Marina I. Levadneva, Irina V. Myznikova, Svetlana E. Pavlova, Larisa A. Romanova, Larisa A. Fedorova, et al.

    Congenital chlamydia infection develops as a result of the intranatal transmission of the pathogen Chlamydia trachomatis from mother to fetus, more often occurs in the form of conjunctivitis, symptoms of which appear in the second to third weeks of a child’s life, or atypical pneumonia developing at 2–3 months of an infant’s life. The clinical picture of the pneumonia is characterized by an obsessive paroxysmal whooping pertussis-like cough with a moderately pronounced symptom of intoxication. Rare manifestations and complications of chlamydial infection in the form of encephalitis, myocarditis, recurrent otitis media in children under 6 months of age are described. Congenital ureaplasma and mycoplasma infection caused by pathogenic or opportunistic types of urogenital mycoplasmas and ureaplasmas more often occurs in the form of atypical pneumonia, which develops in 2–3 weeks of a child’s life. It is characterized by a gradual onset with catarrhal syndrome with the addition of a dry, intense paroxysmal cough with a moderately pronounced intoxication syndrome. In premature infants, the course of the disease is more severe, cases of meningitis, sepsis, and myocarditis have been described. Ureaplasma infection is one of the independent risk factors for the development of bronchopulmonary dysplasia and retinopathy in premature infants. The main criterion for the diagnosis of congenital ureaplasma, mycoplasma or chlamydia infection is the isolation of the deoxyribonucleic acid of the pathogen in biological media by polymerase chain reaction in the presence of clinical and/or laboratory data For the treatment of chlamydia, ureaplasma and mycoplasma infections in newborns and young children, antibacterial drugs from the macrolide group are used in most cases The duration of the course of therapy and the method of administration depends on the severity of the clinical manifestations of infection in the child, the results of laboratory and instrumental studies.


  • Противосудорожная активность производных имидазол-4,5-дикарбоновых кислот на моделях коразоловых и никотиновых судорог у мышей

    by Екатерина Е. Яковлева, Ксения К. Ситдикова, Варвара Г. Яковлева, Евгений Р. Бычков, Петр Д. Шабанов

    В опытах на мышах на моделях судорог, вызванных коразолом и никотином при внутрибрюшинном введении, исследовали противосудорожную активность новых лигандов NMDA-рецепторного комплекса — производных имидазол-4,5-дикарбоновых кислот. Установлено, что на модели коразоловых судорог соединения ИЭМ-2044 и ИЭМ-2295 оказывают выраженное противосудорожное действие. На модели никотиновых судорог противосудорожная активность выявлена для соединений ИЭМ-2044, ИЭМ-2295 и ИЭМ-2296. Показано, что противосудорожная активность соединений ИЭМ-2044, ИЭМ-2295 сопоставима с таковой у препарата сравнения — вальпроевой кислоты.

  • Diagnosis and treatment of transient neonatal thrombocytopenia (Draft clinical recommendations for discussion by specialists)

    by Dmitry O. Ivanov, Galina N. Chumakova, Ekaterina N. Balashova, Tamara V. Belousova, Elena V. Bem, Anastasia Y. Kazantseva, Marina I. Levadneva, Irina V. Myznikova, Svetlana E. Pavlova, Aleksandra S. Panchenko, et al.

    Transient neonatal thrombocytopenia occurs with a frequency of 0.7–0.9% and is divided by etiological factor into primary (alloimmune and transimmune) and secondary (symptomatic) thrombocytopenia, according to the time of occurrence of thrombocytopenia is divided into early and late. The main clinical manifestation of thrombocytopenia is hemorrhagic syndrome of varying severity, which occurs in 20–30% of newborns with thrombocytopenia, in other newborns thrombocytopenia is asymptomatic. The most severe clinical symptom is intracranial hemorrhages, which occur in 10–30% of cases. The most common types of bleeding of the platelet-vascular type are petechiae, ecchymoses, nosebleeds, melena, hematuria, cephalohematoma and other types of bleeding. In dynamics, symptoms of posthemorrhagic anemia may appear with massive bleeding (pallor, tachycardia, tachypnea, decreased blood pressure). The main criterion for the diagnosis of transient neonatal thrombocytopenia is a decrease in the number of platelets below the reference values for a given gestational and chronological age of a newborn child. To diagnose the type of thrombocytopenia, a thorough collection of maternal anamnesis is necessary, examination of parents if they suspect the immune nature of the disease, diagnosis of the disease as a result of which thrombocytopenia has developed, if it is secondary. Correction of thrombocytopenia, if indicated, is carried out by intravenous administration of platelet concentrate. If the immune nature of thrombocytopenia with severe thrombocytopenia is suspected and/or the presence of moderate and higher hemorrhagic syndrome, the administration of normal human immunoglobulin is recommended. If immunoglobulin therapy for immune thrombocytopenia is ineffective, glucocorticoids are prescribed.


  • Open Access

    Diagnosis and treatment of infection specific to the perinatal period (Draft clinical recommendations for discussion by neonatologists and pediatricians)

    by Dmitry O. Ivanov, Alexandra S. Panchenko, Larisa A. Fedorova, Ekaterina N. Balashova, Elena V. Bem, Nazar M. Zelenin, Irina V. Myznikova, Marina I. Levadneva, Anna S. Nabieva, Svetlana E. Pavlova, et al.

    Perinatal infections occupy a leading place among the causes of neonatal morbidity, maternal and perinatal mortality. Infections are among the main causes of termination of pregnancy and premature birth. The practical recommendations presented in the work are intended for doctors of obstetric institutions in order to make a clinical diagnosis of an infection specific to the perinatal period, the tactics of examination and treatment of newborn children. The clinical recommendations correspond to the latest scientific data on the topic, contain information that is applied to the practical activities of a neonatologist, intensive care specialist and pediatrician. These clinical recommendations contain information about infections specific to the perinatal period, including the definition, frequency of occurrence, etiology of infections, pathogenetic mechanisms of disease development Numerous high-risk factors for infection of the fetus and newborn are described in detail. The document discusses and proposes the classification of the disease, the criteria for the adoption of the diagnosis. The features of the clinical picture of the disease are described, it is noted that the inflammatory process in a newborn child can be localized in any organ or acquire a systemic (generalized) character, in some cases, the ingress of an infectious agent into a macroorganism is not necessarily accompanied by clinical manifestations, which indicates an asymptomatic or subclinical course of infection. The recommendations provide advanced laboratory and instrumental diagnostics. The stages of treatment are described, including the choice and correction of antibacterial therapy, taking into account the peculiarities of the mother’s anamnesis, the child’s gestation period and the etiology of the disease. These clinical recommendations have been prepared taking into account the level of credibility of the recommendations and the level of reliability of the evidence.These practical recommendations are offered for public discussion and are posted in full on the website of the Ministry of Health of the Russian Federation.


  • Open Access

    Analgesic activity of new ligands of the NMDA receptor complex

    by Ekaterina E. Yakovleva, Mekhriniso T. Kamalova, Mariia A. Brusina, Evgenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov, Камалова Мехринисо

    BACKGROUND: The activation of spinal cord NMDA receptors is a key factor in the pathogenesis of acute and chronic pain. Therefore, the use of existing NMDA antagonists in analgesic schemes and the development of new compounds targeting the NMDA receptor complex are gaining attention. New ligands of the glutamate NMDA receptor complex are derivatives of imidazole-4,5-dicarboxylic acid. The conformational rigidity of the molecules of imidazole-4,5-dicarboxylic acid derivatives allows for increased selectivity of interaction and reduced side effects. AIM: This study aimed to investigate the analgesic effect of new ligands of the glutamate NMDA receptor complex, which are derivatives of imidazole-4,5-dicarboxylic acid, in rats using the tail-flick test and the formalin test. MATERIALS AND METHODS: The analgesic activity of the compounds was examined in a model of acute somatic (thermal) pain in the tail-flick test and model of somatic pain induced by algogens in the formalin test. The tested compounds (IEM-303 and IEM-2044) were administered intraperitoneally at doses of 5, 10, 15, and 20 mg/kg. Мetamizole was used as the comparison drug. RESULTS: The experiments demonstrated a significant dose-dependent analgesic effect of the tested compounds on the experimental models of acute pain at doses of 5–20 mg/kg. The tail-flick latency increased by 1.4–1.7 times in the IEM-2044 and IEM-303 groups compared with the value in the control group. CONCLUSIONS: The analgesic activity of the tested compounds at 10–20 mg/kg doses was comparable to that of metamizole, indicating the prospect of developing these agents and further searching for effective and safe analgesics in this pharmacological class.

  • Open Access

    Antidyskinetic activity of new derivatives of inydazol-4,5-dicarbonic acid in a parkinsonism experimental model due to administration of 6-hydroxydopapine

    by Vladimir D. Dergachev, Ekaterina E. Yakovleva, Maria A. Brusina, Evgenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov

    BACKGROUND: Levodopa therapy currently remains the clinical method of choice for patients with Parkinsons disease. However, in the late stages of the disease, approximately 80% of patients receiving treatment developed levodopa-induced dyskinesia. The studied substances are derivatives of imidazole-4,5-dicarboxylic acid. Their pharmacological effect is produced due to interaction with the recognition site of NMDA receptor, which, together with their high efficiency, implies that they are safer than previously available drugs in this pharmacological group. AIM: To study the antidyskinetic effect of IEM2295 and IEM2296 derivatives of imidazole-4,5-dicarboxylic acid. MATERIALS AND METHODS: The model is based on the toxic effect of 6-hydroxydopamine on rat brain tissue. The first (control) group of rats received injections of only Levodopa and Benserazide, the second group received injections of Levodopa, Benserazide, and the test substance IEM2295, and the third group received injections of Levodopa, Benserazide and the test substance IEM2296. Each group was evaluated based on three criteria: motor function violations, limb dyskinesia, and axial and chewing dyskinesia. The severity of motor functions was graded on a scale of 0 to 4 points at 35, 70, 105, and 140 minutes after injection of the above substances, where 0 and 4 represent the absence and most pronounced degree of pathological movements, respectively. RESULTS: The result analysis showed that the greatest effect on reducing the severity of limb dyskinesia, axial dyskinesia, and chewing dyskinesia in rats was observed at 105 and 140 minutes after injections of the studied substances. Statistically significant differences between the control group and rats receiving injections of the studied substances were revealed at all the time points for limb dyskinesia; i.e., at 35, 105, and 140 minutes for axial dyskinesia and at 105 and 140 minutes for chewing dyskinesia. CONCLUSIONS: In the experimental model of parkinsonism, IEM2295 and IEM2296 show antiparkinsonian and antidyskinetic activity because they reduce the severity of motor function disorders in rats with levodopa-induced dyskinesia. The results indicate the prospects for continued development of these substances and further research for effective and safe antiparkinsonian agents among compounds of this class.

  • Investigation of antiparkinsonian activity of new imidazole-4,5-dicarboxylic acid derivatives on the experimental model of catalepsy

    by Vladimir D. Dergachev, Ekaterina E. Yakovleva, Maria A. Brusina, Evgeny R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov

    Introduction: To study the antiparkinsonian activity of new ligands of the glutamate NMDA receptor complex – 1,2–substituted imidazole-4,5-dicarboxylic acids – on an experimental model of catalepsy caused by haloperidolintraabdominal injections in rats. Materials and methods: The experiments were performed on Wistar rats weighing 300-350 g, obtained from the Rappolovo nursery of the Russian Academy of Medical Sciences (Leningrad Region). The animals were kept in standard plastic cages in vivarium conditions with free access to water and food at a temperature of 22±2 °C and in the experiment were divided into several groups (6 animals each). All the experiments were carried out in the autumn-winter period. The animals were kept in accordance with the rules of laboratory practice (GLP), regulatory documents ”Sanitary Rules for the Device, Equipment and Maintenance of Vivarium” and the Order of the Ministry of Health and Social Development of the Russian Federation dated 23.08.2010 No. 708n “On Approval of the Rules of Laboratory Practice”. Imidazole-dicarboxylic acid derivatives (IEM-2295, IEM-2296) were injected intraperitoneally at doses from 5 mg/kg to 40 mg/kg simultaneously with haloperidol at a dose of 1 mg/kg, after which the duration and severity of catalepsy were evaluated after 30, 60, 120 minutes from 0 to 6 points according to the Morpurgo method. Results: The severity of catalepsy with the injection of IEM-2295 decreased on average to 3 points, while in the control group it remained at the level of 6 points throughout the observation. However, the severity of catalepsy with the introduction of IEM-2296 decreased to an average of 4 points, but the effect itself lasted longer than with the introduction of IEM-2295. Thus, it was noted that by the 120th minute of observation, the severity of catalepsy in rats receiving the IEM-2295 compound averaged 5 points, whereas in animals receiving IEM-2296 – 3 points. Discussion: Basing on the results of our work and similar experiments, we can conclude that the studied compounds, which are not channel blockers, have an active effect on dopaminergic neurotransmission, because of which the symptoms of catalepsy that occur when haloperidol is injected to rats were stopped to one degree or another. Conclusion: The studied substances exhibit antiparkinsonian activity on an experimental haloperidol model of catalepsy in rats and are promising for development as potential therapies for neurodegenerative diseases. Further study of these compounds and other ligands from the NMDA-blocker group in a wider sample on the catalepsy model, as well as on other models of Parkinsonism, is required. Graphical Abstract


  • Open Access

    Role of glutamate receptor complex in the organism. Ligands of NMDA receptors in neurodegenerative processes – a modern state of the problem

    by Vladimir D. Dergachev, Ekaterina E. Yakovleva, Eugenii R. Bychkov, Levon B. Piotrovskiy, Petr D. Shabanov

    (S)-glutamic acid (glutamate) is the main excitatory mediator in the central nervous system, responsible for regulating of many physiological functions. Dysfunction of the glutamatergic system characterizes of many pathological conditions in neurology and psychiatry, and the aberrant function of glutamate receptors plays a key role in the development of neurodegenerative processes. Glutamate is crucial for many aspects of normal brain function, including memory, learning, and motor planning. In addition, glutamate is involved in the regulation of the peripheral nervous and endocrine systems. Glutamate receptors are critically important molecules necessary for the physiological functioning of the brain: they modulate neurotransmission and regulate the strength of excitatory and inhibitory transmission in the nervous system. In this regard, the use of drugs that affect glutamatergic transmission has an impact on the most important processes of neuronal transmission. The research and development of pharmacological agents involved in the processes of glutamate transmission is a relevant task of modern neuropsychopharmacology and has a purpose to improve the effectiveness and safety of available glutamatergic molecules.